Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 14/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.50 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306651 | 0.90 | CCR9 (0.58) | CCR9HSD17B2CCR2PIK3CD | |
| SCHEMBL305646 | 0.90 | CCR9 (0.55) | CCR9HSD17B2CCR2 | |
| SCHEMBL10223749 | 0.89 | CCR9 (0.52) | CCR9HSD17B2BDKRB1CCR2CYP2C9 | |
| SCHEMBL306137 | 0.89 | CCR9 (0.57) | CCR9HSD17B2CCR2 | |
| SCHEMBL10223709 | 0.89 | CCR9 (0.57) | CCR9HSD17B2CCR2 | |
| SCHEMBL10223720 | 0.89 | CCR9 (0.58) | CCR9HSD17B2CCR2 | |
| SCHEMBL305736 | 0.88 | PIK3CD (0.57) | CCR9HSD17B2CCR2PIK3CD | |
| SCHEMBL10223632 | 0.87 | CCR9 (0.58) | CCR9HSD17B2CCR2 | |
| SCHEMBL10223772 | 0.87 | CCR9 (0.73) | CCR9HSD17B2CCR2PIK3CD | |
| SCHEMBL10223770 | 0.87 | CCR9 (0.54) | CCR9HSD17B2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CCR9 2/4885HSD17B2 2899/4885BDKRB1 138/4885 |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CCR9 2/4885HSD17B2 2899/4885BDKRB1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.